Skip to main content
. 2021 May 14;12:672271. doi: 10.3389/fimmu.2021.672271

Table 1.

Patients’ characteristics at baseline and treatment response.

Characteristics No. of patients(N = 151) Percentage(%)
Age(years), median(IQR) 63(54-69)
 ≥ 63 81 53.6
 < 63 70 46.4
Gender
 Female 36 23.8
 Male 115 76.2
Tumor histology
 Squamous 50 33.1
 Non-Squamous 101 66.9
  Adenocarcinoma 92 60.9
  Others 9 6.0
Stage
Recurrence 29 19.2
Advanced 122 80.8
 IIIB 29 19.2
 IV 93 61.6
ECOG PS
 0-1 147 97.4
 2 4 2.6
Smoking history
 Never 60 39.7
 Now/ever 91 60.3
No. of metastasis sites
 0 32 21.2
 1 72 47.4
 2 33 21.9
 ≥ 3 14 9.3
Mutation type
 EGFR 28 18.5
 KRAS 7 4.6
 Wild-type 116 76.8
Degree of differentiation
 Low 116 76
 Moderate/high 35 23.2
PD-1 inhibitor type
 Pembrolizumab 70 46.4
 Sintilimab 66 43.7
 Toripalimab 15 9.9
Combination regimen
 Chemotherapy 105 69.5
 Anti-angiogenic therapy 18 11.9
 Both 28 18.5
Lines of therapy
 1 61 40.4
 2 49 32.5
 ≥ 3 41 27.2
Radiotherapy
 No 85 56.3
 Yes 66 43.7
Best response
 CR 0 0.0
 PR 46 30.5
 SD 88 58.3
 PD 17 11.3

adenosquamouscarcinoma(n = 3), Sarcomatoid carcinoma(n = 2), otherwise(n = 4).

ALK mutation(n = 0).

ECOG, Eastern Cooperative Oncology Group; PS, performance status.